Welcome to the first FutureFemHealth Pro - a new paid layer where I’ll be sharing more analysis, insights and opinions on the future of women’s health and Femtech.
In its first week, FutureFemHealth Pro made Substack’s top 10 rising sellers list on Substack (appearing at no.9!) and our group of founding members include CEOs, founders, advocates, investors, policy leads and more.
This is the first piece from FutureFemHealth Pro.
Q1 in review
Data note: Figures are based on FutureFemHealth's quarterly funding tracker and represent the data available at the time of publication. We are currently undertaking a full-year reconciliation using FFH Intelligence (FFHi), our expanded methodology and structured women's health funding dataset. This includes transaction-level validation, deduplication and updated classification of qualifying women's health investment. Historical quarterly figures may therefore be revised. Final reconciled 2026 data and analysis will be published in early 2027. For more information, please get in touch: anna@futurefemhealth.com
In Q1, FutureFemHealth tracked $1.24 billion being invested into women’s health across 33 deals.
But that’s a slightly misleading number, since nearly half of it comes from a single deal (WHOOP’s $575 million) - a company that isn’t even positioned as women’s health. So, if we strip that out the figure stands at $665 million - quite different.
What’s actually happening beneath the surface and how should we be thinking about the WHOOP raise?
In this first FutureFemHealth Pro piece, I break down five key takeaways from Q1 and what they mean for where the market goes next.
The full analysis, including all five signals and what they mean for the rest of 2026 is available to FutureFemHealth Pro members.
📊 As a Pro member, you can also download my full spreadsheet of every deal I tracked along with my notes on each*: